News #ECTRIMS2016 – Few Serious Autoimmune Reactions to Lemtrada Treatment Seen in 3 MS Clinical Trials #ECTRIMS2016 – Few Serious Autoimmune Reactions to Lemtrada Treatment Seen in 3 MS Clinical Trials by Patricia Silva, PhD | September 21, 2016 Share this article: Share article via email Copy article link Autoimmune side effects during five years of Lemtrada (alemtuzumab) treatment were generally not serious and mainly affected the thyroid, according to an analysis of patients in three large, Phase 3 clinical trials of the therapy. The data were presented at the Free Communications 1 session of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) 2016 CongressĀ heldĀ in London from Sept. 14 to 17. The study, āAutoimmunity in patients treated With Alemtuzumab for relapsing-remitting multiple sclerosis: 5-Year follow-up of the CARE-MS studies,ā was presented by Colin Dayan, a professor from the Cardiff University School of Medicine in the U.K. The CARE-MS I (NCT00530348) and CARE-MS II (NCT00548405) trials compared Lemtrada to Rebif (interferon beta-1a) therapy in patients who either had not been treated with MS drugs before, or who had a poor response to previous treatment. In a five-year extension study (NCT00930553), researchers followed patients in either treatment arm ofĀ the initial studies, and who received Lemtrada in cases of diseaseĀ relapse. Although treatment with Lemtrada most often gave rise to side effects in the form of reactions to the infusion, autoimmune side effects were also noted, and researchers decided to take a closer look at these particular side effects. During the three trials, researchers routinely monitored autoimmune side effects, and every three months patients had thyroid function tests. Each month, researchers also took a complete blood count, with a closer look at platelet levels and symptoms that could indicate a loss of platelets. Kidney function was monitored with monthly analyses of serum creatinine and a urine sample analysis. Analyzing data from all three trials, involving 811 Lemtrada-treated patients from the first studies and 692 from the extension trial, showed that most autoimmune side effects were mild or moderate. Severe autoimmune side effects were noted 67 times. Importantly, no patients left the trials due toĀ side effects. Most commonly reported side effects involved the thyroid gland, and theyĀ peaked after three years of treatment, then declined during the fourth and fifth years of Lemtrada therapy. Serious adverse effects toĀ the thyroid were rare. In addition, depletion of platelets occurred 22 times, and two patients developed kidney disease. “Autoimmune AEs [adverse events] over 5 years were generally mild or moderate in intensity in alemtuzumab-treated patients from the CARE-MS trials. No patients withdrew from the extension studies due to autoimmune AEs. Consistent with previous reports, most autoimmune AEs were thyroid-related events,” Ā the team concluded. Print This Page About the Author Patricia Silva, PhD PatrĆcia holds a PhD in medical microbiology and infectious diseases from the Leiden University Medical Center, Netherlands, and completed a postdoctoral research fellowship at the Instituto de Medicina Molecular, Lisbon, Portugal. Her work in academia was mainly focused on molecular biology and the genetic traits of infectious agents such as viruses and parasites. PatrĆcia earned several travel awards to present her work at international scientific meetings. She is a published author of several peer-reviewed science articles. Tags adverse events, alemtuzumab, CARE-MS, ECTRIMS2016, Lemtrada, side effects
April 19, 2024 News by Lindsey Shapiro, PhD AAN 2024: Long-term data support early Kesimpta start in relapsing MS
April 18, 2024 Columns by Benjamin Hofmeister Learning how to write a ‘SOAP’ note feels different after an MS diagnosis
April 18, 2024 News by Marisa Wexler, MS AAN 2024: Sustained myelin, nerve cell gains with long-term CNM-Au8